{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-125566","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.097211+00:00","generated_at":"2026-06-07T13:32:10.322842+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond reports Phase 1 topline data for BDTX-1535 in recurrent GBM; durable stabilization seen","bullets":["22 evaluable patients: 3 on therapy >10 months, 1 >6 months, 5 >4 months; historical PFS is 2–4 months.","19 measurable disease patients: 1 confirmed partial response (200 mg QD) and 8 stable disease per RANO criteria.","No new safety signals; AEs were Grade 1–2 diarrhea and rash, consistent with EGFR TKI class.","One patient remains on 100 mg QD for >15 months after progression on temozolomide at 3 months.","Company plans to present dose escalation results at a medical meeting in Q2 2024; window-of-opportunity trial enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-125566","json":"https://secwatch.observer/filing/0001104659-23-125566.json","markdown":"https://secwatch.observer/filing/0001104659-23-125566.md","text":"https://secwatch.observer/filing/0001104659-23-125566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923125566/0001104659-23-125566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923125566/tm2332757d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:32:10.322842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}